The Federal Register

Proposed Data Collections Submitted for Public Comment and Recommendations

Mon, Nov 26 2007 11:00:00 GMT

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 4046395960 and send comments to Maryam Daneshvar, Acting CDC Reports Clearance Officer, 1600 Clifton Road, MSD 74, Atlanta, GA 30333 or send an e mail to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected;

Proposed Data Collections Submitted for Public Comment and Recommendations

Mon, Nov 26 2007 11:00:00 GMT

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 4046395960 and send comments to Maryam I. Daneshvar, CDC Acting Reports Clearance Officer, 1600 Clifton Road, MSD74, Atlanta, GA 30333 or send an email to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c)
[[Page 65967]]
ways to enhance the quality, utility, and clarity of the information

Proposed Data Collections Submitted for Public Comment and Recommendations

Mon, Nov 26 2007 11:00:00 GMT

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 6395960 or send an email to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of Management and Budget, Washington, DC or by fax to (202) 3956974. Written comments should be received within 30 days of this notice. Proposed Project

Evaluation of the SpanishLanguage Campaign ``Good Morning Arthritis, Today You Will Not Defeat Us.''NewNational Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

Arthritis affects nearly 43 million Americans, or about one in every five people, and is the leading cause of disability among adults in t

New Animal Drugs For Use in Animal Feeds; Florfenicol

Mon, Nov 26 2007 11:00:00 GMT

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the approval of a supplemental new animal drug application (NADA) filed by ScheringPlough Animal Health Corp. The supplemental NADA provides for the use of florfenicol by veterinary feed directive (VFD) for the control of mortality in freshwaterreared salmonids due to furunculosis associated with Aeromonas salmonicida.

Determination That ELOXATIN (Oxaliplatin for Injection), 50 and 100 Milligrams Per Vial, Sterile Lyophilized Powder

Mon, Nov 26 2007 11:00:00 GMT

The Food and Drug Administration (FDA) has determined that ELOXATIN (oxaliplatin for injection), 50 and 100 milligrams (mg) per vial, sterile lyophilized powder for injection, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for oxaliplatin sterile lyophilized powder for injection, 50 and 100 mg/ vial.

National Toxicology Program (NTP); NTP Interagency Center for the Evaluation of Alternative Toxicological Methods

Mon, Nov 26 2007 11:00:00 GMT

NICEATM announces availability of the ICCVAM Test Method Evaluation Report: In Vitro Ocular Toxicity Test Methods for Identifying Severe Irritants and Corrosives (NIH Publication 074517). The report describes four ocular toxicity test methods evaluated by

Proposed Collection; Comment Request; Questionnaire Cognitive Interview and Pretesting (ARP/DCCPS/NCI)

Mon, Nov 26 2007 11:00:00 GMT

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: Title: Questionnaire Cognitive Interview and Pretesting. Type of Information Collection Request: NEW. Need and Use of Information Collection: The purpose of the data collection is to conduct cognitive interviews, focus groups, Pilot household interviews, and experimental research in laboratory and field settings, both for applied questionnaire evaluation and more basic research on response errors in surveys. The most common evaluation method is the cognitive interview, in which a questionnaire design specialist interviews a volunteer participant. The interviewer administers the draft surve

NIH Consensus Development Conference: Hydroxyurea Treatment for Sickle Cell Disease; Notice

Mon, Nov 26 2007 11:00:00 GMT

Notice is hereby given of the National Institutes of Health (NIH) ``NIH Consensus Development Conference: Hydroxyurea Treatment for Sickle Cell Disease'' to be held February 2527, 2008, in the NIH Natcher Conference Center, 45 Center Drive, Bethesda, Maryland 20892. The conference will begin at 8:30 a.m. on February 25 and 26, at 9 a.m. on February 27, and will be open to the public.

Sickle cell disease is an inherited blood disorder that affects between 50,000 and 75,000 people in the United States. It is most common among people whose ancestors come from subSaharan Africa, South and Central America, the Middle East, India, and the Mediterranean basin. Sickle cell disease occurs when an infant inherits the gene for sickle hemoglobin from both parents (Hb SS, or sickle cell anemia) or the gene for sickle hemoglobin from one parent and another abnormal hemoglobin gene from the other parent. Each year, approximately 2,000 babies with sickle cell disease are born in the United States. The

National Center on Minority Health and Health Disparities; Notice of Closed Meeting

Mon, Nov 26 2007 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center on Minority Health and Health Disparities Special Emphasis Panel, R13 Conference Grant Review.

Date: December 19, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Lorrita Watson, PhD.

National Center on Minority Health and Health Disparities; Notice of Closed Meeting

Mon, Nov 26 2007 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

Name of Committee: National Center on Minority Health and Health Disparities Special Emphasis Panel, Community Based Participatory Research (CBPR) Meeting.

Date: December 1618, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington DC 20015.

Contact

National Eye Institute; Notice of Closed Meetings

Mon, Nov 26 2007 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial
[[Page 65972]]
property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel, NEI Clinical Grant Application Review.

Date: December 3, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Houmam H. Araj, PhD., Scie

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Mon, Nov 26 2007 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

[[Page 65973]]

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Frequent Hemdialysis Network (FHN).

Date: January 4, 2008.

Time: 2 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telep

National Institute of Environmental Health Sciences; Notice of Closed Meeting

Mon, Nov 26 2007 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel, Signaling Pathways in Stages of Mammary Tumorigenesis.

Date: December 19, 2007.

Time: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: NIEHS/National Institutes of Health, Building 4401, East Campus, 79 T.W. Alexander Drive, Research Triangle Pa

National Institute of Mental Health; Notice of Closed Meeting

Mon, Nov 26 2007 11:00:00 GMT

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

Name of Committee: National Institute of Mental Health Special Emphasis Panel, MLSCN HTS ASSAY.

Date: December 14, 2007.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: St. Gregory Hotel, 2033 M Street, NW., Washington, DC 20036.

Contact Person: Yong Yao, PhD., Scientific Review Administrator, Division of Extramural Activities,

Office of the Director, National Institutes of Health; Amended Notice of Meeting

Mon, Nov 26 2007 11:00:00 GMT

Notice is hereby given of a change in the meeting of the Recombinant DNA Advisory Committee, December 3, 2007, 8 a.m. to December 5, 2007, 10:30 a.m., National Institutes of Health, Building 31, Floor 6C, 31 Center Drive, Conference Room 10, Bethesda, MD, 20892, which was published in the Federal Register on November 13, 2007, 72 FR 218 page 63917.

On December 4, 2007, the Recombinant DNA Advisory Committee meeting will be held from 8 a.m. to 11:30 a.m. and begin again at 2:30 p.m. to 5:30 p.m. instead of meeting from 8 a.m. to 3 p.m. The meeting is open to the public.

Dated: November 15, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 075814 Filed 112307; 8:45 am]
BILLING CODE 414001M